Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LTI-03 · 2 trials · 2 indications
Incidence of TEAEs by dose
| Arm | Type | Description |
|---|---|---|
| (1) 2.5 mg LTI-03 capsule BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (2) 2.5 mg LTI-03 capsules BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (1) Placebo capsule BID | PLACEBO_COMPARATOR | Lactose powder |
| (2) Placebo capsules BID | PLACEBO_COMPARATOR | Lactose powder |
| 2.5 mg LTI-03 BID | EXPERIMENTAL | 2.5 mg LTI-03 BID x 14 days |
| 5 mg LTI-03 BID | EXPERIMENTAL | 5 mg LTI-03 BID x 14 days |
| Placebo | PLACEBO_COMPARATOR | Matching placebo BID x 14 days |
| Name | Type | Description |
|---|---|---|
| LTI-03 | DRUG | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| Dry Powder Inhaler | DEVICE | Plastiape Monodose RS01 Model 7 |
| Placebo | DRUG | Lactose powder |
Inclusion Criteria: 1. Male or female age 40 years or older. 2. Willing and able to provide written informed consent. 3. Diagnosis of IPF within 5 years of Screening as confirmed by a centrally read HRCT of the chest as defined by the ATS/ERS/JRS/ALAT guideline. HRCT lung fibrosis by central read d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
| Trevi Therapeutics, Inc. | TRVI | 1 | PHASE1 | NAL |